Quality statements
Statement 1 Adults with a 5% or more total lifetime risk of developing ovarian cancer have a discussion about risk-reducing surgery. [new 2025]
Statement 2 (placeholder) CA125 blood test – age-specific thresholds.
Statement 3 Adults newly diagnosed with non-mucinous high-grade epithelial ovarian cancer are offered panel germline genetic testing. [new 2025]
Statement 4 Adults newly diagnosed with stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer are offered tumour genetic testing. [new 2025]
Statement 5 Adults with high-risk stage 1 ovarian cancer, or stage 2 to 4 ovarian cancer, have both surgery and chemotherapy discussed as a treatment option by a specialist gynaecological cancer multidisciplinary team. [new 2025]
In 2025 this quality standard was updated, and statements prioritised in 2012 were replaced [new 2025]. For more information, see update information.
The previous version of the quality standard on ovarian cancer is available as a pdf.